• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

11
11
8
5
5

COUNTRY

5
2
1
1
1

CATEGORIES

  • 23
  • 7
  • 6
  • 6
  • 4
  • 3
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1

PRICE

12
14
18
52

PUBLISHED

2
12
21
52

PRODUCT TYPE

42
10

Search "Eisai: Pipeline, Products, Performance and Potential" returned 52 results.

PRODUCT TITLE

Eisai Co., Ltd. (4523) - Financial and Strategic SWOT Analysis Review

Eisai Co., Ltd. (4523) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by The...

July 2014
FROM
Global Pharmaceutical & Biotechnology Outlook 2013: Japan Pharma Global Pharmaceutical & Biotechnology Outlook 2013: Japan Pharma - Product Thumbnail Image

Global Pharmaceutical & Biotechnology Outlook 2013: Japan Pharma

Global Pharmaceuticals and biotechnology outlook - Japan Pharma The coming years will see Japan pharma regaining its status as innovator driven with Edoxaban for Daiichi Sankyo, Canagliflozin for Mitsubishi...

January 2013
FROM
The Pain Market Outlook to 2016 The Pain Market Outlook to 2016 - Product Thumbnail Image

The Pain Market Outlook to 2016

The heterogeneity of pain necessitates a wide range of analgesics with different modes of action and delivery methods As such, many different classes of drugs co-exist in the pain market However, despite...

July 2011
FROM

Ganaxolone (Epilepsy) - Forecast and Market Analysis to 2022

Ganaxolone (Epilepsy) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Ganaxolone (Epilepsy) - Forecast and Market Analysis to 2022”....

February 2013
FROM

Brivaracetam (Epilepsy) - Forecast and Market Analysis to 2022

Brivaracetam (Epilepsy) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Brivaracetam (Epilepsy) - Forecast and Market Analysis to...

February 2013
FROM

VX-765 (Epilepsy) - Forecast and Market Analysis to 2022

VX-765 (Epilepsy) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “VX-765 (Epilepsy) - Forecast and Market Analysis to 2022”. Epilepsy...

February 2013
FROM

Halaven ( Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022

Halaven ( Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and...

June 2013
FROM

PharmaPoint: Epilepsy - Japan Drug Forecast and Market Analysis to 2022

PharmaPoint: Epilepsy - Japan Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Epilepsy - Japan Drug Forecast and Market Analysis to...

February 2013
FROM

PharmaPoint: Epilepsy - Germany Drug Forecast and Market Analysis to 2022

PharmaPoint: Epilepsy - Germany Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Epilepsy - Germany Drug Forecast and Market Analysis...

February 2013
FROM

PharmaPoint: Epilepsy - UK Drug Forecast and Market Analysis to 2022

PharmaPoint: Epilepsy - UK Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Epilepsy - UK Drug Forecast and Market Analysis to 2022”....

February 2013
FROM

PharmaPoint: Epilepsy - France Drug Forecast and Market Analysis to 2022

PharmaPoint: Epilepsy - France Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Epilepsy - France Drug Forecast and Market Analysis to...

February 2013
FROM

PharmaPoint: Epilepsy - Spain Drug Forecast and Market Analysis to 2022

PharmaPoint: Epilepsy - Spain Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Epilepsy - Spain Drug Forecast and Market Analysis to...

February 2013
FROM

PharmaPoint: Epilepsy - Italy Drug Forecast and Market Analysis to 2022

PharmaPoint: Epilepsy - Italy Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Epilepsy - Italy Drug Forecast and Market Analysis to...

February 2013
FROM

PharmaPoint: Epilepsy - India Drug Forecast and Market Analysis to 2022

PharmaPoint: Epilepsy - India Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Epilepsy - India Drug Forecast and Market Analysis to...

February 2013
FROM

PharmaPoint: Epilepsy - China Drug Forecast and Market Analysis to 2022

PharmaPoint: Epilepsy - China Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Epilepsy - China Drug Forecast and Market Analysis to...

February 2013
FROM

Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Summary GlobalData, the industry analysis specialist, has released its new report, “Chemotherapy-Induced...

February 2012
FROM

PharmaPoint: Epilepsy - US Drug Forecast and Market Analysis to 2022

Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction The...

February 2013
FROM

PharmaPoint: Alzheimer's Disease - Japan Drug Forecast and Market Analysis to 2022

PharmaPoint: Alzheimer’s Disease - Japan Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Alzheimer’s Disease - Japan Drug Forecast and...

July 2013
FROM
R&D Trends: Sepsis R&D Trends: Sepsis - Product Thumbnail Image

R&D Trends: Sepsis

Improvements in clinical trial design and advances in biomarker research hold the key to a tailored approach to sepsis therapy Despite Eli Lilly’s Xigris being the only licensed therapeutic, the sepsis...

April 2011
FROM
Pipeline Insight: Epilepsy - Past successes hard to emulate in highly genericized market Pipeline Insight: Epilepsy - Past successes hard to emulate in highly genericized market - Product Thumbnail Image

Pipeline Insight: Epilepsy - Past successes hard to emulate in highly genericized market

Introduction Sales of antiepileptic drugs totaled $3.5 billion in 2009 across the seven major markets (US, Japan, France, Germany, Italy, Spain and the UK). Datamonitor anticipates the combination...

May 2010
FROM
Loading Indicator